{"@context":"https:\/\/schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"name":"ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1\/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)","item":"https:\/\/www.regionalcancercare.org\/trials\/rosetta-hcc-206-an-open-label-multi-center-randomized-phase-1-2-study-of-pumitamig-alone-or-in-combination-with-ipilimumab-in-participants-with-first-line-advanced-or-unresectable-hepatocellular-ca\/#breadcrumbitem"}]}